Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals has made amendments and widened its existing R&D pact with GlaxoSmithKline (GSK), originally signed in October 2007 targeting leucyl-tRNA synthetase (LeuRS).
Subscribe to our email newsletter
With this revised deal, Anacor has decided to give an option to GSK for extending its rights for the bacterial enzyme targeting LeuRS, as well as to add new programs for tuberculosis (TB) and malaria using Anacor’s boron chemistry platform.
As per the changes, GSK is now responsible to pay a sum of $5m as an upfront payment to Anacor as well as additional milestones and research funding of up to $11.3m by the end of 2012.
Anacor is also entitled to obtain additional milestones and royalties on future sales of resulting products from GSK.